Toragen Revenue and Competitors
Estimated Revenue & Valuation
- Toragen's estimated annual revenue is currently $697.5k per year.
- Toragen's estimated revenue per employee is $77,500
Employee Data
- Toragen has 9 Employees.
- Toragen grew their employee count by -10% last year.
Toragen's People
Name | Title | Email/Phone |
---|---|---|
1 | Founder | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | CFO | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Director R & D | Reveal Email/Phone |
6 | Senior Scientist | Reveal Email/Phone |
Toragen Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Toragen?
Toragen is focused on repurposing anti-viral drugs and developing novel immunotherapies to treat viral-associated cancers. Our team is comprised of industry leaders with decades of experience in early stage biotechnology startups, translational drug development, and practice-changing Phase III clinical trials. oragen is preparing to initiate a Phase I clinical trial with its lead compound in HPV-associated malignancies and is seeking investor funding for research and development.
keywords:N/AN/A
Total Funding
9
Number of Employees
$697.5k
Revenue (est)
-10%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.7M | 9 | N/A | N/A |
#2 | $0.7M | 9 | N/A | N/A |
#3 | $0.7M | 9 | N/A | N/A |
#4 | $0.7M | 9 | N/A | N/A |
#5 | $0.7M | 9 | N/A | N/A |